Paul Mampilly is editor of the FDA Trader. Paul has almost 25 years of investment experience, maintaining almost every kind of job in finance. He’s covered biotech and health care as an analyst and portfolio manager for major international banks such as Deutsche Bank, ING, and Bankers Trust.

Posts byPaul Mampilly

,

How to Stop a Murderer

Biotech breakthroughs and other transformative innovations are a few of the brightly shining spots in the U.S. economy. In fact, Paul Mampilly believes this is the golden age of biotech investing, and that you can earn massive returns while investing in companies with drugs that benefit all of humanity. Read on for his latest example…

// //